Compare TransMedics Group Inc (TMDX) vs Consumer Staples Select Sector SPDR Fund (XLP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Consumer Staples Select Sector SPDR Fund — how do they compare? TransMedics Group Inc trades at $77.87 (market cap $2.74B), while Consumer Staples Select Sector SPDR Fund trades at $83.43 (market cap $13.50B). The key difference: Consumer Staples Select Sector SPDR Fund is far larger — about 4.9× TransMedics Group Inc's market cap, and Consumer Staples Select Sector SPDR Fund is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold TransMedics Group Inc for 24 Days and Consumer Staples Select Sector SPDR Fund for 72 Days on average.
| TMDX | XLP | |
|---|---|---|
Market Cap | $2.74B | $13.50B |
Volume | 949,331 | 14,599,953 |
Sector | Health | — |
52-Week High | $150.42 | $90.00 |
52-Week Low | $61.99 | $75.61 |
Typical Hold Time | 24 Days | 72 Days |
Enterprise Value | $3.13B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $77.87, down 3.95% on the day, amid a bearish technical signal and recent earnings misses. The company maintains strong profitability with a 22.69% net income margin and 36.28% ROE, though 2026 projections show margin compression. Analyst consensus remains bullish with a $99.75 price target, but sentiment is clouded by multiple legal investigations into fiduciary duties announced in late August and September 2026.
The stock faces near-term pressure from technical weakness and legal overhangs, but solid fundamentals and analyst conviction suggest long-term potential if execution improves. Key risks include ongoing legal scrutiny, margin pressures from heavy investment, and volatility around future earnings reports.
XLP (Consumer Staples Select Sector SPDR ETF) trades at $83.42, up 2.11% with a bullish technical signal supported by moving averages and oscillators. The ETF shows strong defensive characteristics amid market volatility, with 100% analyst buy ratings and a forthcoming dividend. Recent news highlights its outperformance versus discretionary sectors and competitive positioning against peers like VDC and IYK.
Outlook remains positive given defensive sector strength and favorable expense ratio, though risks include interest rate sensitivity and consumer spending shifts. The ETF's focus on household staples provides stability, but elevated RSI levels suggest near-term consolidation potential before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Consumer Staples Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →
